Resilient's Bravo device has the potential to make an enormous impact in breast cancer treatment and lumpectomy procedures, with potential applications in the broader reconstructive surgery space.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/30/23 | undisclosed | First Round |
TechGROWTH Ohio | undisclosed |
